BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

905 related articles for article (PubMed ID: 33332002)

  • 1. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
    Dos Santos RG; Hallak JEC; Crippa JAS
    Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
    Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
    Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
    McPartland JM; Duncan M; Di Marzo V; Pertwee RG
    Br J Pharmacol; 2015 Feb; 172(3):737-53. PubMed ID: 25257544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
    Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
    Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.
    Blebea NM; Pricopie AI; Vlad RA; Hancu G
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
    Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
    Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of Medical Cannabis.
    Amin MR; Ali DW
    Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.
    Millán-Guerrero RO; Isais-Millán S
    Gac Med Mex; 2019; 155(5):471-474. PubMed ID: 32091020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabidiol Interferes with Establishment of Δ
    DeVuono MV; La Caprara O; Petrie GN; Limebeer CL; Rock EM; Hill MN; Parker LA
    Cannabis Cannabinoid Res; 2022 Feb; 7(1):58-64. PubMed ID: 33998876
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.
    Campos AC; Moreira FA; Gomes FV; Del Bel EA; Guimarães FS
    Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3364-78. PubMed ID: 23108553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constituents of Cannabis Sativa.
    Rock EM; Parker LA
    Adv Exp Med Biol; 2021; 1264():1-13. PubMed ID: 33332000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phytocannabinoid Pharmacology: Medicinal Properties of
    Sampson PB
    J Nat Prod; 2021 Jan; 84(1):142-160. PubMed ID: 33356248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.
    Myers AM; Siegele PB; Foss JD; Tuma RF; Ward SJ
    Br J Pharmacol; 2019 May; 176(10):1552-1567. PubMed ID: 29338068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Enantiomer-Specific Signaling of Cannabidiol at CB
    Bosquez-Berger T; Wilson S; Iliopoulos-Tsoutsouvas C; Jiang S; Wager-Miller J; Nikas SP; Mackie KP; Makriyannis A; Straiker A
    Mol Pharmacol; 2022 Dec; 102(6):259-268. PubMed ID: 36153039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment.
    Asth L; Iglesias LP; De Oliveira AC; Moraes MFD; Moreira FA
    Epilepsy Behav; 2021 Aug; 121(Pt B):106832. PubMed ID: 31839498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cannabimimetic effects of selected minor cannabinoids and Terpenoids in mice.
    Wiley JL; Marusich JA; Blough BE; Namjoshi O; Brackeen M; Akinfiresoye LR; Walker TD; Prioleau C; Barrus DG; Gamage TF
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110984. PubMed ID: 38417478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis y los sistemas exocannabinoide y endocannabinoide. Su uso y controversias.
    Millán-Guerrero RO; Isais-Millán S
    Gac Med Mex; 2019; 155(5):508-512. PubMed ID: 31695229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.